NOVAVAX, INC. (NVAX) Total liabilities 2016–2025
NOVAVAX, INC. (NVAX) total liabilities at each fiscal year-end, per SEC filings.
$1.3BFY2025 · since FY2016: $399.8M → $1.3B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $1.3B | -40.3% |
| FY2024 | $2.2B | -13.1% |
| FY2023 | $2.5B | -13.1% |
| FY2022 | $2.9B | -1.2% |
| FY2021 | $2.9B | +206.6% |
| FY2020 | $955.3M | +166.1% |
| FY2019 | $359.0M | -4.5% |
| FY2018 | $375.9M | -7.0% |
| FY2017 | $404.2M | +1.1% |
| FY2016 | $399.8M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice